Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.63 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | FPR1 | P21462 | 1/20 | 0.48 |
| ▸ | FPR3 | P25089 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18642577 | 0.88 | FFAR4 (0.56) | FFAR1FFAR4 | |
| SCHEMBL18642579 | 0.87 | FFAR1 (0.49) | FFAR1FFAR4 | |
| SCHEMBL18657070 | 0.86 | FFAR1 (0.45) | FFAR1FFAR4 | |
| SCHEMBL3248092 | 0.84 | FFAR4 (0.55) | FFAR1FFAR4 | |
| SCHEMBL18642580 | 0.83 | FFAR1 (0.50) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL3884363 | 0.83 | FFAR4 (0.54) | FFAR1FFAR4 | |
| Hydrochloric Acid SCHEMBL7690739 | 0.83 | FFAR4 (0.54) | FFAR1FFAR4 | |
| SCHEMBL14762667 | 0.82 | FFAR4 (0.59) | FFAR1FFAR4 | |
| SCHEMBL3884361 | 0.81 | FFAR4 (0.52) | FFAR1FFAR4 | |
| SCHEMBL8531827 | 0.81 | FFAR4 (0.52) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026018-B | Diphenylacetylene compound | 国立大学法人大阪大学 | 2021-01-15 | — | — | CN | disclosed |
| US-10577396-B2 | Tolan compound | OSAKA UNIVERSITY (JP) | 2020-03-03 | — | — | US | disclosed |
| US-10577396-B2 | Tolan compound | OSAKA UNIVERSITY (JP) | 2020-03-03 | — | — | US | disclosed |
| US-20180258141-A1 | TOLAN COMPOUND | OSAKA UNIVERSITY (JP) | 2018-09-13 | — | — | US | disclosed |
| WO-2017047807-A1 | TOLAN COMPOUND | 国立大学法人大阪大学 | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577396-B2 | Tolan compound | TAP1, GRN, TSG101 | FFAR1 3436/4885FFAR4 3969/4885CHRM2 4470/4885 |
| US-20180258141-A1 | TOLAN COMPOUND | TAP1, GRN, TSG101 | FFAR1 3436/4885FFAR4 3969/4885CHRM2 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.